Starboard has approached two former Pfizer executives, Ian Read and Frank D’Amelio, to assist in its efforts, and they have ...

U.S. sales of RSV vaccines from GSK and Pfizer are down significantly after regulators narrowed the targeted age group and ...

To overcome that, pharma sales and marketing teams look to data ... this work to consulting firms that specialise in developing target lists and engagement messaging. But this often proves to ...

Big pharma companies are making big cuts to make up for declining drug sales and legal settlements draining some New Jersey firms. Johnson & Johnson, Bayer and Bristol Myers Squibb plan to ...

While initial estimates projected peak sales nearing $500 million ... Piper has downgraded Supernus Pharmaceuticals to Neutral from Overweight, with a price target of $36, down from $41.

The Federal Trade Commission staff is criticizing pharmaceutical benefit managers, which negotiate drug discounts. But ...

Lexicon Pharmaceuticals Inc (LXRX) stock saw a modest uptick, ending the day at $1.69 which represents a slight increase of $0.08 or 4.97% from the prior close of $1.61. The stock opened at $1.63 and ...

The firm set a price target for Lumos Pharma at $16.00 ... This trend supports analysts' anticipation of a sales decline in the current year, as noted in the InvestingPro Tips.

(Alliance News) - Celadon Pharmaceuticals PLC on Wednesday announced it has signed a five-year sales contract with Valeos Pharma AS. Celadon Pharmaceuticals is a London-based pharmaceutical ...

On Wednesday, UroGen Pharma (NASDAQ:URGN) shares retained its Outperform rating and a $40.00 price target from Oppenheimer ... to surpass $1 billion in sales over time. The optimism follows ...

Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast Truist Securities raises the price target for Corcept Therapeutics to $76 ...

The firm set a price target for Lumos Pharma at $16.00, reflecting an optimistic view of ... This trend supports analysts' anticipation of a sales decline in the current year, as noted in the ...